Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome (PCOS)

• ClinicalTrials.gov Identifier: NCT01607320
• Recruitment Status: Terminated
• First Posted: May 30, 2012
• Results First Posted: June 1, 2015
• Last Update Posted: September 20, 2018
• Sponsor: Bruce Lessey
• Information provided by (Responsible Party): Bruce Lessey, Prisma Health-Upstate

Study Description

Brief Summary:

This study examines Raloxifene versus Clomiphene to induce ovulation in women with polycystic ovarian syndrome (PCOS).

Condition or disease	Intervention/treatment	Phase
Polycystic Ovarian Syndrome	Drug: Raloxifene; Drug: Clomiphene	Not Applicable

Detailed Description:

Clomiphene citrate (CC) is the major pharmaceutical treatment of anovulation in polycystic ovary syndrome, used for over 40 years. Despite the vast experience using this drug, the pregnancy rates associated with its use are low and recent large studies from Australia regarding birth defects suggest that CC may be associated with birth defects. Alternatives to CC are limited. Another selective estrogen receptor modulator, Raloxifene (RAL) does not have the long half life exhibited by CC, and has recently been shown to be equivalent to CC in terms of ability to induce ovulation in PCOS women. In addition, prior studies have demonstrated potential benefits on markers of uterine receptivity in a cell line model by blocking estrogen activity. Beyond this, there are no studies to examine whether Raloxifene is an effective oral agent for the treatment of women desiring pregnancy, but the investigators' hypothesis is that Raloxifene will work as well as CC but be better at establishment and maintenance of pregnancy than CC

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 3 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Investigator)
• Primary Purpose: Treatment
• Official Title: Effect of Raloxifene on Ovulation in Women With Polycystic Ovarian Syndrome.
• Study Start Date: June 2012
• Actual Primary Completion Date: March 2013
• Actual Study Completion Date: March 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Raloxifene; 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7	Drug: Raloxifene; Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal; Other Name: Provera
Active Comparator: Clomiphene; 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7	Drug: Clomiphene; Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal; Other Name: Provera

Outcome Measures

Primary Outcome Measures :

1. Pregnancy [ Time Frame: 4 months ]
   Time frame will vary depending on how many treatment cycles it takes to get pregnant. If no pregnancy occurs, study participation will likely be about 4 months.

Secondary Outcome Measures :

1. Ovulation [ Time Frame: Cycle day 22-24 ]
   If ovulation does not occur during the first treatment cycle, subject will be withdrawn from study.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 36 Years (Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Women aged 18 to 36
2. BMI > 19 & < 40
3. PCOS diagnosis as evidenced by:

Oligo- and/or anovulation (< 6 cycles per year) and one of the following:

• Clinical and/or biochemical signs of hyperandrogenism
• Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome)

Exclusion Criteria:

1. Use of ovulation induction agents within the past 6 months
2. Positive pregnancy test before taking study medications
3. History or current thromboembolic disorder
4. Coronary artery disease such as heart attack or stroke
5. Tobacco use or history within the past 6 months
6. History of pelvic inflammatory disease and tubal factor infertility
7. Congenital adrenal hyperplasia

8. Diabetes Mellitus

   • Any subject on Metformin must "wash out" for 30 days prior to screening
9. History of endometriosis
10. Known male factor infertility

Contacts and Locations

Locations

United States, South Carolina

Greenville Hospital System

Greenville, South Carolina, United States, 29605

Sponsors and Collaborators

Bruce Lessey

Investigators

• Principal Investigator: Bruce A. Lessey, MD, PhD; Greenville Hospital System

More Information

• Responsible Party: Bruce Lessey, MD, PhD. and Professor of Clinical Obstetrics & Gynecology, Dept of OB/GYN, Prisma Health-Upstate
• ClinicalTrials.gov Identifier: NCT01607320
• Other Study ID Numbers: 9469
• First Posted: May 30, 2012
• Results First Posted: June 1, 2015
• Last Update Posted: September 20, 2018
• Last Verified: August 2018

Keywords provided by Bruce Lessey, Prisma Health-Upstate:

PCOS; Infertility; Anovulation

Additional relevant MeSH terms:

Polycystic Ovary Syndrome; Syndrome; Disease; Pathologic Processes; Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Endocrine System Diseases; Raloxifene Hydrochloride; Medroxyprogesterone Acetate; Clomiphene; Medroxyprogesterone; Estrogen Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Fertility Agents, Female; Fertility Agents; Reproductive Control Agents; Selective Estrogen Receptor Modulators; Estrogen Receptor Modulators; Bone Density Conservation Agents; Contraceptive Agents, Hormonal; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Male; Antineoplastic Agents, Hormonal